CBIO

Crescent Biopharma
CBIO

Overview Fund Trends Analyst Outlook Journalist POV

35 hedge funds and large institutions have $15.8M invested in Crescent Biopharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
35
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$37K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$57.3K
2
+$37K
3
+$19K
4
Millennium Management
Millennium Management
New York
+$18.2K
5
Jane Street
Jane Street
New York
+$11K

Top Sellers

1
-$309K
2
-$125K
3
-$103K
4
PVI
Pura Vida Investments
New York
-$100K
5
BlackRock
BlackRock
New York
-$59.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$6K
27
$6K
28
$5K
29
$3K
30
$2K
31
$1K
32
$288
33
–
34
–
35
–
36
–
37
–
38
–
39
–
40
–
41
–
1
2